<DOC>
	<DOC>NCT01541215</DOC>
	<brief_summary>This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Children and adolescents between the ages of 1016 years. Subjects cannot turn 17 years and 11 months before the end of treatment (52 weeks) Diagnosis of type 2 diabetes mellitus and treated for at least 30 days with: diet and exercise alone, diet and exercise in combination with metformin monotherapy, diet and exercise in combination with metformin and a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin, diet and exercise in combination with a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin HbA1c: 7.011% (inclusive) if diet and exercise treated or 6.511% (inclusive) if treated with metformin as monotherapy, basal insulin as monotherapy or metformin and basal insulin in combination Body mass index (BMI) above 85% percentile of the general age and gender matched population Type 1 diabetes Maturity onset diabetes of the young (MODY) Use of any antidiabetic agent other than metformin and/or basal insulin within 90 days prior to screening Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator History of chronic pancreatitis or idiopathic acute pancreatitis Any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial Uncontrolled hypertension, treated or untreated above 99th percentile for age and gender in children Known or suspected abuse of alcohol or drugs/narcotics</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>